Literature DB >> 2086223

First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.

M Jonsson, M Walder, A Forsgren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2086223     DOI： 10.1007/BF01967392

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  18 in total

1.  Norfloxacin resistance in a clinical isolate of Escherichia coli.

Authors:  H Aoyama; K Sato; T Kato; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

2.  Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.

Authors:  L M Fisher; J M Lawrence; I C Josty; R Hopewell; E E Margerrison; M E Cullen
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

3.  Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid.

Authors:  R M Lumish; C W Norden
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

4.  A critical evaluation of nalidixic acid in urinary-tract infections.

Authors:  A R Ronald; M Turck; R G Petersdorf
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

Review 5.  The new quinolones and their combinations with other agents for therapy of severe infections.

Authors:  N Desplaces; L Gutmann; J Carlet; J Guibert; J F Acar
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

6.  Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.

Authors:  D C Hooper; J S Wolfson; K S Souza; C Tung; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

7.  Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones.

Authors:  M E Cullen; A W Wyke; R Kuroda; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].

Authors:  G Aubert; C Puech; F Lucht; M Loboguerrero; M Denis; G Dorche
Journal:  Pathol Biol (Paris)       Date:  1989-10

9.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

10.  Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance.

Authors:  D Greenwood; M Osman; J Goodwin; W A Cowlishaw; R Slack
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790
View more
  5 in total

1.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 2.  Risk factors for acquisition of multiply drug-resistant gram-negative bacteria.

Authors:  I M Gould
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

3.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

4.  In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.

Authors:  K S Thomson; C C Sanders; M E Hayden
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 5.  Mechanisms of quinolone resistance.

Authors:  B Wiedemann; P Heisig
Journal:  Infection       Date:  1994       Impact factor: 3.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.